<DOC>
	<DOC>NCT02005549</DOC>
	<brief_summary>This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin will be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated time on study treatment is 3-12 months.</brief_summary>
	<brief_title>A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>female patients, 1870years of age; histologicallyproven invasive breast cancer; no prior or current neoplasm except for nonmelanoma skin cancer, or in situ cancer of the cervix; no distant disease/secondary cancer. pregnant or lactating women; preoperative local treatment for breast cancer; prior or concurrent systemic antitumor therapy; clinically significant cardiac disease.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>